Cyclic HIV-1 protease inhibitors derived from mannitol: Synthesis, inhibitory potencies, and computational predictions of binding affinities

被引:157
作者
Hulten, J
Bonham, NM
Nillroth, U
Hansson, T
Zuccarello, G
Bouzide, A
Aqvist, J
Classon, B
Danielson, UH
Karlen, A
Kvarnstrom, I
Samuelsson, B
Hallberg, A
机构
[1] UNIV UPPSALA, UPPSALA BIOMED CTR, DEPT ORGAN PHARMACEUT CHEM, S-75123 UPPSALA, SWEDEN
[2] UNIV UPPSALA, UPPSALA BIOMED CTR, DEPT BIOCHEM, S-75123 UPPSALA, SWEDEN
[3] UNIV UPPSALA, UPPSALA BIOMED CTR, DEPT MOL BIOL, S-75124 UPPSALA, SWEDEN
[4] LINKOPING UNIV, DEPT CHEM, S-58183 LINKOPING, SWEDEN
[5] MEDIVIR AB, S-14144 HUDDINGE, SWEDEN
[6] UNIV STOCKHOLM, ARRHENIUS LAB, DEPT ORGAN CHEM, S-10691 STOCKHOLM, SWEDEN
关键词
D O I
10.1021/jm960728j
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Ten C-2-symmetric cyclic urea and sulfamide derivatives have been synthesized from L-mannonic gamma-lactone and D-mannitol. The results of experimental measurement of their inhibitory potencies against HIV-1 protease were compared to calculated free energies of binding derived from molecular dynamics (MD) simulations. The compounds were selected, firstly, to enable elucidation of the role of stereochemistry for binding affinity (1a-d) and, secondly, to allow evaluation of the effects of variation in the link to the P1 and P1' phenyl groups on affinity (la and 2-5). Thirdly, compounds with hydrogen bond-accepting or -donating groups attached to the phenyl groups in the P2 and P2' side chains (6 and 7) were selected. Binding free energies were estimated by a linear response method, whose predictive power for estimating binding affinities from MD simulations was demonstrated.
引用
收藏
页码:885 / 897
页数:13
相关论文
共 79 条
[31]   HIV PROTEASE - A NOVEL CHEMOTHERAPEUTIC TARGET FOR AIDS [J].
HUFF, JR .
JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (08) :2305-2314
[32]  
Hughes D.L., 1992, ORG REACT, V42, P335, DOI [10.1002/0471264180.OR042.02, DOI 10.1002/0471264180.OR042.02]
[33]   HUMAN IMMUNODEFICIENCY VIRUS-1 PROTEASE .2. USE OF PH RATE STUDIES AND SOLVENT KINETIC ISOTOPE EFFECTS TO ELUCIDATE DETAILS OF CHEMICAL MECHANISM [J].
HYLAND, LJ ;
TOMASZEK, TA ;
MEEK, TD .
BIOCHEMISTRY, 1991, 30 (34) :8454-8463
[34]   SYNTHESIS OF C2-SYMMETRICAL HIV-1 PROTEASE INHIBITORS FROM D-MANNITOL [J].
JADHAV, PK ;
WOERNER, FJ .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1992, 2 (04) :353-356
[35]   SYNTHESIS OF 8-MEMBERED CYCLIC SULFAMIDES - NOVEL HIV-1 PROTEASE INHIBITORS [J].
JADHAV, PK ;
WOERNER, FJ .
TETRAHEDRON LETTERS, 1995, 36 (36) :6383-6386
[36]   STRUCTURE AT 2.5-A RESOLUTION OF CHEMICALLY SYNTHESIZED HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PROTEASE COMPLEXED WITH A HYDROXYETHYLENE-BASED INHIBITOR [J].
JASKOLSKI, M ;
TOMASSELLI, AG ;
SAWYER, TK ;
STAPLES, DG ;
HEINRIKSON, RL ;
SCHNEIDER, J ;
KENT, SBH ;
WLODAWER, A .
BIOCHEMISTRY, 1991, 30 (06) :1600-1609
[37]   A SURFACE CONSTRAINED ALL-ATOM SOLVENT MODEL FOR EFFECTIVE SIMULATIONS OF POLAR SOLUTIONS [J].
KING, G ;
WARSHEL, A .
JOURNAL OF CHEMICAL PHYSICS, 1989, 91 (06) :3647-3661
[38]   ACTIVE HUMAN IMMUNODEFICIENCY VIRUS PROTEASE IS REQUIRED FOR VIRAL INFECTIVITY [J].
KOHL, NE ;
EMINI, EA ;
SCHLEIF, WA ;
DAVIS, LJ ;
HEIMBACH, JC ;
DIXON, RAF ;
SCOLNICK, EM ;
SIGAL, IS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (13) :4686-4690
[39]   RATIONAL DESIGN OF POTENT, BIOAVAILABLE, NONPEPTIDE CYCLIC UREAS AS HIV PROTEASE INHIBITORS [J].
LAM, PYS ;
JADHAV, PK ;
EYERMANN, CJ ;
HODGE, CN ;
RU, Y ;
BACHELER, LT ;
MEEK, JL ;
OTTO, MJ ;
RAYNER, MM ;
WONG, YN ;
CHANG, CH ;
WEBER, PC ;
JACKSON, DA ;
SHARPE, TR ;
ERICKSONVIITANEN, S .
SCIENCE, 1994, 263 (5145) :380-384
[40]  
LAM PYS, 1994, Patent No. 19329